IPO Details
Bidding Dates
29 Sept 25 - 01 Oct 25
Price Range ₹
181 - 191
Total Equity
₹ 230.35Cr
Lot Size
75
Exchange Status
BSE,NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
2.08×
Qualified Institutional Buyers
2.02×
Employees
2.01×
Retail Investors
2.08×
Total subscription Rate
2.03×
IPO Timeline
Offer start
29 Sept 2025
Offer end
01 Oct 2025
Allotment
03 Oct 2025
Refund initiation
06 Oct 2025
Demat transfer
06 Oct 2025
Listing
07 Oct 2025
Offer start
29 Sept 2025
Offer end
01 Oct 2025
Allotment
03 Oct 2025
Refund initiation
06 Oct 2025
Demat transfer
06 Oct 2025
Listing
07 Oct 2025
About Company
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company specializing in turnkey project execution. The company provides end-to-end solutions including cleanroom facilities, modular systems, HVAC technology, process equipment, purified water systems, and clean air solutions, catering to global bio-pharma, life sciences, food & beverage, IT, semiconductor, and aerospace industries. Its offerings cover the entire bio-pharma lifecyclefrom design and engineering to manufacturing, installation, and project management, ensuring compliance with international standards. Fabtech has built a reputation as a key turnkey engineering solutions provider backed by in-house software capabilities, a diversified client base, and proven execution across challenging geographies. The company benefits from its Fabtech Group parentage and an experienced leadership team, driving efficient project delivery and mandate conversion.
Year Founded
26-10-2018
Promotor Details
Naushad Panjwani
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 94.61 | 0 |
| Share Capital | 30644834 | 0 |
Offer to Public
1,20,60,000.00 Cr
Project Details
- Funding working capital requirements of our Company - 1270cr
- Pursuing inorganic growth initiatives through acquisitions - 300cr
Objectives
- Funding working capital requirements of our Company
- Pursuing inorganic growth initiatives through acquisitions
- andGeneral Corporate Purposes
Highlights
- Strong revenue (46% YoY) and PAT (71% YoY) growth shows scalability and operational efficiency.
- Covers clean air, clean water, modular systems, and turnkey projects across multiple industries, reducing dependency on a single segment.
- High ROE (30.46%) and ROCE (24.46%) indicate effective capital utilization and profitability.
- Ability to deliver projects across diverse geographies and dosage forms enhances credibility.
- Backed by Fabtech Group and experienced leadership, offering stability, brand value, and execution expertise.
Challenges
- Borrowings increased significantly from ₹9.88 Cr (FY24) to ₹54.62 Cr (FY25), which could strain future cash flows if not managed well.
- P/B ratio of 3.57 suggests premium valuation, leaving less room for error in execution.
- Heavy reliance on capital-intensive biopharma and allied industries, which are sensitive to global economic and regulatory cycles.
- Any delays or cost overruns in large projects can impact profitability and margins.
- With only 185 employees, scaling up for larger orders may require rapid workforce expansion and training.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2023 | 21,259.33 | 278.59 | 4,645.30 | 4,645.30 | 14.3408 |
| 2024 | 26,748.96 | 294.48 | 2,721.74 | 2,721.74 | 8.4023 |
| 2025 | 42,413.17 | 3,239.22 | 2,721.74 | 2,721.74 | 8.4023 |
| 2022 | 17,096.79 | 278.59 | 4,645.30 | 4,645.30 | 14.3408 |
